secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tevogen Bio Holdings Inc. (TVGN)
CIK:        0001860871
Form:       8-K
Filed at:   2024-01-24T23:59:59+00:00
Accession:  0001493152-24-003611
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Semper Paratus shifts combined Tevogen Bio listing target to Nasdaq from NYSE American
--------------------------------------------------------------------------------

- Parties agreed to seek Nasdaq listing for New Tevogen common stock and public warrants instead of NYSE American.
- Prospectus Supplement filed on Jan 24, 2024 to revise prior proxy statement/prospectus.
- Shareholder meeting to vote on business combination with Tevogen Bio remains scheduled for Jan 29, 2024.
- Semper Paratus (LGST, LGSTW) will redomesticate to Delaware and rename to Tevogen Bio Holdings Inc. upon closing.
- Tevogen Bio is a clinical-stage immunotherapy company with wholly owned IP including three granted patents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860871/000149315224003611/0001493152-24-003611-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860871/000149315224003611/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-003611

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer